Online inquiry

IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12700MR)

This product GTTS-WQ12700MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets DLL4 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_019074.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 54567
UniProt ID Q9NR61
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ12700MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3944MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BCD-145
GTTS-WQ2491MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 212
GTTS-WQ1732MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ADC-1013
GTTS-WQ8005MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GZ-402668
GTTS-WQ9044MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ4404MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-663513
GTTS-WQ11970MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MM-005
GTTS-WQ5039MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CA Exendin-4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW